Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | ITGAL | P20701 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28408084 | 0.89 | DPP7 (0.46) | DPP7HPGDLMNATAS1R3TAS1R1 | |
| SCHEMBL20704237 | 0.87 | DPP7 (0.45) | DPP7ALDH1A1HPGDLMNABAZ2B | |
| SCHEMBL14348619 | 0.85 | DPP7 (0.43) | DPP7HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30962669 | 0.85 | DPP7 (0.43) | DPP7HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1655858 | 0.83 | ALDH1A1 (0.51) | DPP7ALDH1A1LMNATAS1R3TAS1R1 | |
| SCHEMBL30561507 | 0.83 | ALDH1A1 (0.51) | DPP7ALDH1A1LMNATAS1R3TAS1R1 | |
| SCHEMBL14590719 | 0.83 | DPP7 (0.59) | DPP7ALDH1A1HPGDLMNABAZ2B | |
| SCHEMBL11988475 | 0.80 | NOTUM (0.42) | DPP7BAZ2BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5768587 | 0.80 | LMNA (0.43) | DPP7ALDH1A1HPGDLMNARAB9A | |
| SCHEMBL450030 | 0.79 | HSD17B3 (0.44) | BAZ2BNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2005-07-14 | — | — | US | claimed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153960-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | DPP7 578/4885ALDH1A1 178/4885HPGD 116/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | DPP7 2392/4885ALDH1A1 389/4885HPGD 358/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | DPP7 578/4885ALDH1A1 178/4885HPGD 116/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | DPP7 1954/4885ALDH1A1 261/4885HPGD 84/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | DPP7 1920/4885ALDH1A1 327/4885HPGD 125/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | DPP7 578/4885ALDH1A1 178/4885HPGD 116/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | DPP7 2052/4885ALDH1A1 192/4885HPGD 99/4885 |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AADAC, ASPH, EGLN3 | DPP7 1486/4885ALDH1A1 540/4885HPGD 34/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | DPP7 578/4885ALDH1A1 178/4885HPGD 116/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | DPP7 2052/4885ALDH1A1 192/4885HPGD 99/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | DPP7 1920/4885ALDH1A1 327/4885HPGD 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.